Drug Profile
Tolimidone - Melior Pharmaceuticals
Alternative Names: CP-26154; MLR-1023Latest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Melior Pharmaceuticals, Inc.
- Developer Adhera Therapeutics; Bukwang Pharmaceutical; Melior Pharmaceuticals, Inc.
- Class Antihyperglycaemics; Hepatoprotectants; Phenyl ethers; Small molecules
- Mechanism of Action Lyn protein-tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- Preclinical COVID 2019 infections; Non-alcoholic steatohepatitis; Type 1 diabetes mellitus